UK markets open in 7 hours 14 minutes

Sanofi (SNYNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
108.84+4.34 (+4.15%)
At close: 10:07AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close104.50
Bid0.00 x 0
Ask0.00 x 0
Day's range108.84 - 108.84
52-week range91.55 - 114.80
Avg. volume11,672
Market cap138.947B
Beta (5Y monthly)0.36
PE ratio (TTM)19.40
EPS (TTM)5.61
Earnings dateN/A
Forward dividend & yield3.52 (3.37%)
Ex-dividend date06 May 2022
1y target estN/A
  • Globe Newswire

    Sanofi: Information concerning the total number of voting rights and shares – May 2022

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,527,121,390 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n

  • Motley Fool

    Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA

    Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.

  • Motley Fool

    Why Sanofi May Be a Frontrunner in Endemic COVID-19

    Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.